• Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting

    Wednesday May 19th 2021

  • Sequana Medical announces strong top-line results from RED DESERT alfapump DSR® study and expansion of DSR® development programme

    Tuesday May 11th 2021

  • New cancer immunotherapy treatment enters clinical phase

    Thursday April 29th 2021

  • Precirix partners with Evergreen to expand North American clinical trial supply

    Wednesday April 28th 2021

  • ViroVet successful with second vaccine based on new vaccine technology, Rega Institute assesses development of human version

    Monday March 22nd 2021

  • Consortium led by eTheRNA immunotherapies awarded EU Commission TIGER Grant of EUR 6.9 million

    Sunday March 21st 2021

  • Galapagos reports primary endpoint for the ongoing filgotinib MANTA and MANTA-RAy safety studies

    Thursday March 4th 2021

  • Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

    Thursday February 11th 2021

  • Your news here?

  • VUB scientist Mathieu Vinken coordinates prestigious European research into animal-free methods for testing chemical substances

    Wednesday February 3rd 2021

  • argenx announces “GO” Decision in ADHERE trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy following interim analysis

    Tuesday February 2nd 2021

  • Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study

    Tuesday January 12th 2021


Strategic Partners